News Release
Ivermectin and COVID-19: Legal Intervention in Clinical Practice Exposes Patients to Serious Harm
Clinicians, scientists and public health leaders on the front lines of our response to the COVID-19 pandemic remain eager for new safe and effective therapies to treat the disease. The suffering and loss of life due to COVID-19 are tragic. We empathize with patients and their loved ones and are working to ensure the best care and outcomes for all.
IDSA Journals Launch Call for Associate Editor Applications
IDSA’s journals, Clinical Infectious Diseases, The Journal of Infectious Diseases and Open Forum Infectious Diseases, are launching a call for applications for all qualified individuals with interest in joining the journals as associate editors.
Infectious Diseases Society of America Announces Next Editor-in-Chief of Clinical Infectious Diseases
IDSA is pleased to announce that Paul E. Sax, MD, FIDSA, has been selected as the next editor-in-chief of Clinical Infectious Diseases. Dr. Sax will succeed Robert T. Schooley, MD, on July 1, 2022, following Dr. Schooley’s years of outstanding service to the journal and the Society.
IDSA Converts IDA&E Task Force to New Committee to Continue Inclusion, Diversity, Access and Equity Focus
In recognition of the importance of inclusion, diversity, access and equity as long-term priorities and core values for IDSA, the Society’s Board of Directors recently approved the creation of a permanent IDA&E Committee.
More than $1.7 Million in IDSA Foundation Grant Funds Attracts Diverse Minds to Alzheimer’s Research
The grant funds, which were awarded through the Foundation’s Microbial Pathogenesis in Alzheimer’s Disease Grant program, were dispersed among 11 researchers representing a wide range of research fields and institutions across the U.S.
IDSA Response to CDC’s Updates on Masking Guidance
The Omicron SARS-CoV-2 variant is more transmissible than earlier variants, which means that wearing the right mask is even more important.
Recommendations for Ensuring Equitable Access to Oral Therapies for Treating COVID-19
Many hospitals and health departments are experiencing the greatest strain on their systems and workforce since the COVID-19 pandemic was declared nearly two years ago.
Infectious Diseases Society of America Announces Next Editor-in-Chief of The Journal of Infectious Diseases
IDSA is pleased to announce that Cynthia L. Sears, MD, FIDSA, has been selected as the next editor-in-chief of The Journal of Infectious Diseases. Dr. Sears will succeed Martin S. Hirsch, MD, FIDSA, at the end of 2022, following his distinguished two decades of service to JID.
What You Need to Know About COVID-19 and the Omicron Variant
As scientists and clinicians learn more about the Omicron variant, IDSA highlights four things we know right now that can help reduce transmission and the risk of disease.
IDSA and SHEA Statement on CDC Updated Guidance for Health Care Personnel Isolation and Quarantine to Mitigate Staffing Shortages
IDSA and the SHEA support the updated interim guidance from the CDC and Prevention for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 and Mitigating Healthcare Personnel Staffing Shortages.
IDSA Response to FDA’s Authorization of First Oral Antiviral for Treatment of COVID-19
IDSA supports the FDA’s emergency use authorization for Paxlovid, an oral anti-viral for the treatment of mild-to-moderate COVID-19. This authorization comes at a key moment as the nation and the world face climbing case counts and increased stress on health care systems.